Stockscreener 앱 받기
2.53%
전일 마감가:
$26.50
열려 있는:
$26.265
하루 거래량:
36.96M
Relative Volume:
0.59
시가총액:
$146.78B
수익:
$62.79B
순이익/손실:
$9.84B
주가수익비율:
15.05
EPS:
1.7156
순현금흐름:
$10.38B
1주 성능:
-0.23%
1개월 성능:
+2.95%
6개월 성능:
+6.25%
1년 성능:
-3.44%
1일 변동 폭
$25.75
$26.39
1주일 범위
$25.51
$26.83
52주 변동 폭
$20.91
$27.69
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.82 | 150.67B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,016.76 | 930.38B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.45 | 540.74B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
217.66 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.96 | 292.08B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
60.45 | 279.45B | 46.69B | 15.29B | 9.25B | 3.4329 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
TrumpRx Launch: Pfizer (PFE) and Other Pharma Giants Join New Pl - GuruFocus
Wolfe Research Adjusts Price Target on Pfizer to $25 From $24, Maintains Underperform Rating - marketscreener.com
Has Novavax cracked the code for survival in the vaccine arena? - Pharma Voice
Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal - Yahoo Finance
Sleeping Bruxism Treatment Market Size to Reach USD 1,132.09 Million by 2033, Driven by Rising Awareness of Sleep Disorders and Oral Health Complications – SNS Insider - GlobeNewswire Inc.
Biosimilars Market Huge Growth in Future Scope 2026-2033 | Amgen Inc., Pfizer Inc., Samsung Bioepis Co., Ltd. - openPR.com
CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks - TipRanks
Pfizer Reshapes Pipeline With Novavax Deal And ViiV Exit - simplywall.st
Pfizer (PFE) Among Firms Facing Medicare Drug Price Negotiations - GuruFocus
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider - Yahoo! Finance Canada
US names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - marketscreener.com
US names HIV, arthritis drugs for next Medicare price talks - Reuters
What are Wall Street analysts' target price for Pfizer stock? - MSN
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Yahoo! Finance Canada
Pfizer Enters into Agreement with Walgreens to Help Eligible U.S. Adults Navigate Their Healthcare Journey - Pfizer
The Analyst Verdict: Pfizer In The Eyes Of 7 Experts - Benzinga
Pfizer (PFE) Analyst Rating Update: Cantor Fitzgerald Raises Pri - GuruFocus
Why Is Pfizer Stock Rising Tuesday? - Benzinga
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline - Finviz
CMA Seeks To Appeal Re-Do Of £70M Pfizer, Flynn Drug Fines - Law360
118,500 Shares in Pfizer Inc. $PFE Acquired by Y Intercept Hong Kong Ltd - MarketBeat
These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively - Yahoo Finance
Macrolide Antibiotics Market to Witness Stunning Growth - openPR.com
Pfizer vs. Merck Stock And JNJ - Forbes
With 66% Ownership of the Shares, Pfizer Inc. (NYSE:PFE) Is Heavily Dominated by Institutional Owners - 富途牛牛
Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance (NYSE:PFE) - Seeking Alpha
What Are Wall Street Analysts' Target Price for Pfizer Stock? - Barchart.com
Pfizer (PFE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Pfizer Recasts Infectious Disease Focus With ViiV Exit And Matrix M Access - simplywall.st
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
Recent Report Shows That Rep. French Hill Sold Up to $365K Worth of Pfizer Stock - Benzinga
Pfizer Stock Forecast 2026–2030 | Future Outlook - Capital.com
Parthenon LLC Has $1.27 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Callahan Advisors LLC Acquires 43,454 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Avantax Planning Partners Inc. - MarketBeat
Pfizer to exit ViiV Healthcare as GSK and Shionogi reshape ownership - MSN
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance
Quilter Plc Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Sector Gamma AS Increases Stake in Pfizer Inc. $PFE - MarketBeat
UniSuper Management Pty Ltd Increases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Commerzbank Aktiengesellschaft FI Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Refines Vaccine Toolkit With Matrix M Deal And ViiV Exit - simplywall.st
The Best Stocks to Invest $40 in to Start the New Year Off Right - Finviz
Pfizer Inc. $PFE Stock Position Lessened by Resona Asset Management Co. Ltd. - MarketBeat
Rakuten Investment Management Inc. Buys New Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Refocuses Portfolio With Matrix M Deal And ViiV Exit - simplywall.st
Lobbying Update: $2,810,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (NYSE:PFE) Stock Price Down 1.7%Here's What Happened - MarketBeat
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
자본화:
|
볼륨(24시간):